中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
Chinese Journal of Lung Cancer
2015年
10期
621-625
,共5页
张卉%杨新杰%秦娜%李曦%杨惠夷%农靖颖%吕嘉林%吴羽华%张权%张新勇%王敬慧%苏丹%张树才
張卉%楊新傑%秦娜%李晞%楊惠夷%農靖穎%呂嘉林%吳羽華%張權%張新勇%王敬慧%囌丹%張樹纔
장훼%양신걸%진나%리희%양혜이%농정영%려가림%오우화%장권%장신용%왕경혜%소단%장수재
肺肿瘤%表皮生长因子受体%KARS基因%突变%鳞癌
肺腫瘤%錶皮生長因子受體%KARS基因%突變%鱗癌
폐종류%표피생장인자수체%KARS기인%돌변%린암
Lung neoplasms%Epidermal growth factor receptor%KARS gene%Mutation%Squamous
背景与目的表皮生长因子受体（epidermal growth factor receptor, EGFR）突变和KARS基因突变是非小细胞肺癌（non-small cell lung cancer, NSCLC）靶向治疗的重要分子标志，但关于肺鳞癌中EGFR和KARS基因突变情况的报道甚少。本研究旨在分析肺鳞癌EGFR和KRAS基因突变与临床特征的关系。方法收集初治肺鳞癌患者139例，有可供检测的肿瘤组织标本。利用突变富集液相芯片法进行EGFR和KRAS基因突变检测。结果139例肺鳞癌中， EGFR基因突变25例（18%），KRAS基因突变7例（5%），EGFR和KRAS基因同时发生突变1例（0.7%）。女性和不吸烟患者EGFR基因突变率高于男性和吸烟患者（33.3%vs 16.5%,29.6%vs 16.1%），但差异均无统计学意义（P>0.05, P>0.05）；不同年龄、分期及病理取材标本之间差异均无统计学意义（P>0.05）。男性患者KARS基因突变率高于女性患者（5.5%vs 0%），但差异无统计学意义（P>0.05）；在不同年龄、分期、病理取材标本及是否吸烟各亚组分析中KARS基因突变差异无统计学意义（P>0.05）。结论肺鳞癌患者EGFR和KARS基因突变发生率均较低，且都与临床特征无明显相关。肺鳞癌患者使用酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）靶向治疗药物之前，也应检测EGFR基因和KARS基因的突变情况。
揹景與目的錶皮生長因子受體（epidermal growth factor receptor, EGFR）突變和KARS基因突變是非小細胞肺癌（non-small cell lung cancer, NSCLC）靶嚮治療的重要分子標誌，但關于肺鱗癌中EGFR和KARS基因突變情況的報道甚少。本研究旨在分析肺鱗癌EGFR和KRAS基因突變與臨床特徵的關繫。方法收集初治肺鱗癌患者139例，有可供檢測的腫瘤組織標本。利用突變富集液相芯片法進行EGFR和KRAS基因突變檢測。結果139例肺鱗癌中， EGFR基因突變25例（18%），KRAS基因突變7例（5%），EGFR和KRAS基因同時髮生突變1例（0.7%）。女性和不吸煙患者EGFR基因突變率高于男性和吸煙患者（33.3%vs 16.5%,29.6%vs 16.1%），但差異均無統計學意義（P>0.05, P>0.05）；不同年齡、分期及病理取材標本之間差異均無統計學意義（P>0.05）。男性患者KARS基因突變率高于女性患者（5.5%vs 0%），但差異無統計學意義（P>0.05）；在不同年齡、分期、病理取材標本及是否吸煙各亞組分析中KARS基因突變差異無統計學意義（P>0.05）。結論肺鱗癌患者EGFR和KARS基因突變髮生率均較低，且都與臨床特徵無明顯相關。肺鱗癌患者使用酪氨痠激酶抑製劑（tyrosine kinase inhibitors, TKIs）靶嚮治療藥物之前，也應檢測EGFR基因和KARS基因的突變情況。
배경여목적표피생장인자수체（epidermal growth factor receptor, EGFR）돌변화KARS기인돌변시비소세포폐암（non-small cell lung cancer, NSCLC）파향치료적중요분자표지，단관우폐린암중EGFR화KARS기인돌변정황적보도심소。본연구지재분석폐린암EGFR화KRAS기인돌변여림상특정적관계。방법수집초치폐린암환자139례，유가공검측적종류조직표본。이용돌변부집액상심편법진행EGFR화KRAS기인돌변검측。결과139례폐린암중， EGFR기인돌변25례（18%），KRAS기인돌변7례（5%），EGFR화KRAS기인동시발생돌변1례（0.7%）。녀성화불흡연환자EGFR기인돌변솔고우남성화흡연환자（33.3%vs 16.5%,29.6%vs 16.1%），단차이균무통계학의의（P>0.05, P>0.05）；불동년령、분기급병리취재표본지간차이균무통계학의의（P>0.05）。남성환자KARS기인돌변솔고우녀성환자（5.5%vs 0%），단차이무통계학의의（P>0.05）；재불동년령、분기、병리취재표본급시부흡연각아조분석중KARS기인돌변차이무통계학의의（P>0.05）。결론폐린암환자EGFR화KARS기인돌변발생솔균교저，차도여림상특정무명현상관。폐린암환자사용락안산격매억제제（tyrosine kinase inhibitors, TKIs）파향치료약물지전，야응검측EGFR기인화KARS기인적돌변정황。
Background and objective Activating mutations in epidermal growth factor receptor (EGFR) and KARS are important markers in non-small cell lung cancer. However, EGFR and KARS gene mutations in lung squamous cell carcinoma are rarely reported. hTe aim of this study was to analyze EGFR and KARS gene mutation rate and their relationship with clinical features in patients with lung squamous cell carcinomas. Methods A total of 139 patients undergoing treatment for na?ve lung squamous cell carcinomas with tumor tissue samples available for testing were recruited. EGFR and KARS mutation statuses of the tumor samples were detected using a mutant enriched liquid chip. Results Of the 139 cases of lung squamous cell carcinoma, EGFR mutations were detected in 25 cases (18%), KARS mutations were detected in 7 cases (5%), and the pres-ence of both EGFR and KARS mutations was detected in 1 case (0.7%). EGFR mutations occurred more otfen in females than in males (33.3%vs 16.5%) and in patients that never smoked than in those who smoke (29.6%vs 16.1%). However, the differ-ence did not reach statistical signiifcance (P>0.05). No signiifcant differences were observed in age, stage, and different biopsy type. KARS mutations occurred more otfen in males than in females (5.5%vs 0%), but the difference did not reach statistical signiifcance (P>0.05). No signiifcant differences were observed in age, stage, different biopsy type, and smoking status (P>0.05). Conclusion EGFR and KARS mutations were low in lung squamous cell carcinomas, and had no signiifcant correlation with clinical features. Before using tyrosine kinase inhibitor targeted therapy, EGFR and KARS mutations should be detected in pa-tients with lung squamous cell carcinomas.
